Mon, Dec 29, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

UBP consolidates FoHFs expertise with appointment of Larry Morgenthal as CEO and CIO of Alternatives

Tuesday, July 06, 2010
Opalesque Industry Update – Today, Union Bancaire Privée announced that it has appointed Larry Morgenthal as CEO of UBP Asset Management, the Group’s US business. He also assumes the role of Chief Investment Officer of Alternatives.

Mr Morgenthal will spearhead the renewed activity in the company’s fund of hedge funds platform, following the reinforcement of its investment and risk management teams since 2009. UBP has been investing in hedge funds since 1972 and offers a full range of capabilities, from tailored recommendations to commingled funds.

‘The case for hedge funds and their alpha-generation potential is undisputed,’ said Richard Wohanka, CEO of Asset Management and Alternative Investments at UBP. ‘It is time to look at hedge funds in a new way: as core portfolio holdings, rather than as a small part of an alternatives segment. UBP has the right infrastructure to offer clients funds of hedge funds that can enhance the opportunity set for balanced portfolios, and for traditional equity and fixed income investments. Larry has a long track record of building alternative businesses through an understanding of client priorities and I am delighted that he will be leading the Alternatives division at UBP.’

Mr Morgenthal has 18 years of direct involvement in alternative investing and business development, having started his career managing the assets for two large US pension funds, NCR Corporation and Asea Brown Boveri (ABB). He has held senior positions in Bank of America’s Alternative Investment Group, where he headed the overall business and chaired the investment committee, as well as at Opus Capital Group, where he was managing partner, and Ivy Asset Management (BNY Mellon), where he held the roles of COO and later CEO.


Union Bancaire Privée (UBP) is based in Geneva and is one of Switzerland’s leading private banks. Active in the field of asset management for both private and institutional clients and with a very solid balance sheet, the Bank had more than CHF 75 billion (USD 72 billion) in assets under management as at 31 December 2009. UBP employs around 1,200 people in some 20 locations worldwide and provides a complete range of products and innovative investment solutions, both in traditional and alternative asset management, with the aim of seeking out performance and attaining its clients’ objectives. www.ubpbank.com


Bg

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its